comparemela.com

Latest Breaking News On - Prnewswire scisparc ltd - Page 1 : comparemela.com

SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial

/PRNewswire/ SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of.

Exchange commissionScisparc ltdClearmind medicine incCompany or scisparcPrnewswire scisparc ltdClearmind medicineAbout scisparcLooking statementsPrivate securities litigation reform actAnnual reportScisparc ltdHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

SciSparc Presents New Leadership Lineup

/PRNewswire/ SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of.

Amitay weissOz adlerKost forer gabbay kasiererItschak shremScisparc ltdBank poalei agudat israel ltdUniversity of manchesterEngland collegePrnewswire scisparc ltdCollege of managementBusiness marketing developmentOno academic collegeBoard of directors the companyChief executive officerChief financial officerChief financial

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110

/PRNewswire/ SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of.

Eteläuomen läiUnited statesMichael blochTanya gurevichAdi zuloff shaniMovement disorders unitScisparc ltdTourette outpatient clinic at hannover medical schoolHannover medical school inPrnewswire scisparc ltdExchange commissionSackler school of medicineSourasky medical centerAviv sourasky medical centerAviv sourasky medical schoolAviv university

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110

/PRNewswire/ SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of.

Eteläuomen läiUnited statesMichael blochTanya gurevichAdi zuloff shaniMovement disorders unitScisparc ltdTourette outpatient clinic at hannover medical schoolHannover medical school inPrnewswire scisparc ltdExchange commissionSackler school of medicineSourasky medical centerAviv sourasky medical centerAviv sourasky medical schoolAviv university

SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer s Disease

/PRNewswire/ SciSparc Ltd. (NASDAQ: SPRC) (the "Company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat.

Adi zuloff shaniCompany phase iiaScisparc ltdSophie abraham stuchynski israeli alzheimer medical centerDrug administrationPrnewswire scisparc ltdIsraeli medical centerExchange commissionStudy protocol phaseAlzheimer diseaseAbraham stuchynski israeli alzheimerMedical centerChief technology officerLooking statementsPrivate securities litigation reform actAnnual report

vimarsana © 2020. All Rights Reserved.